Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVI...
Shots: The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 pat...
Shots: The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 pat...
Shots: The company initiates the P-II trial, conducted in 2 parts evaluating the c...
Shots: The P-III trial results published in
Shots: The P-II study evaluating the immunogenicity & safety profile of recomb...
Shots: Nuvaxovid (NVX-CoV2373) received expanded authorization from Health Canada...
Shots: The P-II/III trial to evaluate Omicron BA.4/BA.5-Adapted Bivalent Booster (...
Incisive News in 3 Shots.